CKD Bio Corp.

A063160

KR7063160006

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 03/07/2024 am IST			5-day change	1st Jan Change
21,350 ^KRW	+0.47%		-1.16%	-10.48%

2023	CKD Bio Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	CKD Bio Corp.(KOSE:A063160) dropped from S&P Global BMI Index	CI

CKD Bio Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 16, 2022 at 10:54 am IST

CKD Bio Corp. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was KRW 0.00051 million compared to KRW 0.00103 million a year ago. Net loss was KRW 1,204.55 million compared to KRW 1,960.34 million a year ago. Basic loss per share from continuing operations was KRW 220 compared to KRW 357 a year ago. Basic loss per share was KRW 220 compared to KRW 357 a year ago.

Latest news about CKD Bio Corp.

CKD Bio Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
CKD Bio Corp.(KOSE:A063160) dropped from S&P Global BMI Index	18/23/18	CI
CKD Bio Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
CKD Bio Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
CKD Bio Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/22/16	CI
CKD Bio Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/22/16	CI
CKD Bio Corp. Reports Earnings Results for the Full Year Ended December 31, 2021	17/22/17	CI
CKD Bio Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	15/21/15	CI
Exclusive: South Korea's GL Rapha to ship out 10 million Sputnik Light COVID-19 shots this month	14/21/14	RE
Boryung Pharmaceutical : S.Korea's GL Rapha to ship out 10 mln Sputnik Light COVID-19 shots this month	14/21/14	RE
CKD Bio Corp.(KOSE:A063160) added to S&P Global BMI Index	21/20/21	CI
Chong Kun Dang Holdings Corp. completed the acquisition of additional 35.67% stake in Ckd Bio Corporation for KRW 61.6 billion.	12/16/12	CI
Chong Kun Dang Holdings Corp. made an offer to acquire an additional 35.67% stake in Ckd Bio Corporation for KRW 55.9 billion.	19/16/19	CI
Korea Securities Finance Corporation acquired 4.11% stake in Ckd Bio Corporation.	09/15/09	CI
Ckd Bio Corporation Announces Earnings Results for the Full Year Ended December 31, 2012	20/13/20	CI

Chart CKD Bio Corp.

Duration

Period

More charts

Company Profile

CKD Bio Corp. is a Korea-based company specialized in the manufacturing of pharmaceutical products. The Company mainly provides antibiotic ingredients, consisting of demethylchlortetracyclines (DMCTs) and rifampicins. It also provides immunosuppressive agents, including cyclosporin and tacrolimus; remedies for diabetes, such as acarbose, and potassium clavulanate used for beta-lactam inhibitors. The Company distributes its products within domestic market and to overseas markets, such as America, China, Europe, Africa, Southeast Asia, Latin America and the Middle East.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CKD BIO CORP.	-10.48%	8.46Cr
ELI LILLY AND COMPANY	+54.07%	81TCr
NOVO NORDISK A/S	+39.16%	62TCr
JOHNSON & JOHNSON	-7.05%	35TCr
MERCK & CO., INC.	+15.44%	32TCr
ABBVIE INC.	+5.72%	29TCr
ASTRAZENECA PLC	+14.28%	24TCr
ROCHE HOLDING AG	-0.61%	22TCr
NOVARTIS AG	+14.62%	22TCr
AMGEN INC.	+7.42%	17TCr